Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

TXG PEER ANALYSIS

10X Genomics Inc — metric-by-metric comparison with peers and the industry median

TXG10X Genomics Inc

🇺🇸 USA · NASDAQ · Healthcare · Health Information Services

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Health Information Services

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
TXGIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
TXG+199.8%PME-31.5%FONET+128.7%
Year-to-Date (YTD)
TXG+139.2%PME-4.8%FONET+88.2%
1-Year
Split-adjusted
TXG+199.8%WAY-39.3%DOCS-63.1%SLGC—PRVA+24.8%HQY-5.9%
Year-to-Date (YTD)
TXG+139.2%WAY-28.4%DOCS-50.6%SLGC-2.7%PRVA+15.4%HQY+4.0%

Key Metric Comparison

P/E

Lower is better
TXG—PME93.49FONET20.21Median 41.96

ROE

Higher is better
TXG-3.0%PME76.8%FONET15.6%Median 2.7%

Net Margin

Higher is better
TXG-3.5%PME97.6%FONET26.0%Median 1.5%

Revenue Growth

Higher is better
TXG2.3%PME30.3%FONET53.5%Median 7.1%

P/E

Lower is better
TXG—WAY36.31DOCS21.75SLGC—PRVA164.54HQY35.12Median 41.96

ROE

Higher is better
TXG-3.0%WAY3.6%DOCS19.3%SLGC-23.7%PRVA3.1%HQY11.1%Median 2.7%

Net Margin

Higher is better
TXG-3.5%WAY10.9%DOCS30.4%SLGC-159.5%PRVA1.0%HQY17.3%Median 1.5%

Revenue Growth

Higher is better
TXG2.3%WAY18.6%DOCS13.1%SLGC-19.7%PRVA24.7%HQY7.6%Median 7.1%

All Metrics

Valuation
MetricTXGPMEFONETInd. Median
P/E—93.4920.21●41.96
P/B6.1556.422.62●2.50
EV/EBITDA48.73115.2410.38●16.12
P/S7.8391.215.26●2.35
Financial Health
MetricTXGPMEFONETInd. Median
Current Ratio5.906.22●2.311.83
Debt/Equity10.0%1.1%●2.5%22.0%
NetDebt/EBITDA-4.91●-1.16-0.21-0.01
Profitability
MetricTXGPMEFONETInd. Median
Net Margin-3.5%97.6%●26.0%1.5%
ROE-3.0%76.8%●15.6%2.7%
ROA-2.4%56.7%●13.2%1.4%
EBITDA Margin14.6%78.4%●49.6%12.4%
Growth + Dividend
MetricTXGPMEFONETInd. Median
Rev. Growth2.3%30.3%53.5%●7.1%
NI Growth—138.8%●26.6%23.6%
Div. Yield—0.3%●0.0%0.7%
Payout—24.5%0.0%9.6%
Valuation
MetricTXGWAYDOCSSLGCPRVAHQYInd. Median
P/E—36.3121.75●—164.5435.1241.96
P/B6.151.16●4.487.284.763.962.50
EV/EBITDA48.7314.2713.25●—56.2319.2416.12
P/S7.833.966.6144.221.59●6.062.35
Financial Health
MetricTXGWAYDOCSSLGCPRVAHQYInd. Median
Current Ratio5.901.766.0917.79●1.613.441.83
Debt/Equity10.0%37.7%1.1%0.6%●1.2%48.1%22.0%
NetDebt/EBITDA-4.913.21-2.783.31-7.28●1.57-0.01
Profitability
MetricTXGWAYDOCSSLGCPRVAHQYInd. Median
Net Margin-3.5%10.9%30.4%●-159.5%1.0%17.3%1.5%
ROE-3.0%3.6%19.3%●-23.7%3.1%11.1%2.7%
ROA-2.4%2.4%16.4%●-20.8%1.7%6.9%1.4%
EBITDA Margin14.6%35.8%41.3%●-166.7%2.5%34.3%12.4%
Growth + Dividend
MetricTXGWAYDOCSSLGCPRVAHQYInd. Median
Rev. Growth2.3%18.6%13.1%-19.7%24.7%●7.6%7.1%
NI Growth—383.6%●-12.2%—39.3%89.4%23.6%
Div. Yield——————0.7%
Payout——————9.6%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on TXG

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.